https://orcid.org/0000-0003-2237-2756
References
- Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res. 2011;317:1261–1269.
- Ascierto P, Brugarolas BL, Buonaguro L, et al. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018;6:1–14.
- Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–249.
- Olin M, Low W, McKenna D, et al. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induce a CD4+IL17+ response. J Immunother Cancer. 2014;2:4.
- Hatherley D, Lea SM, Johnson S, et al. Structures of CD200/CD200 receptor family and implications for topology, regulation, and evolution. Structure. 2013;21:820–832.
- Patsoukos N, Brown J, Petkova V, et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012;5:ra46.
- Coles SJ, Gilmour MN, Reid R, et al. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia. 2015 Sep;29(9):1952–1954.
- Jens M, Chemnitz R, Parry K, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945–954.
- Xiong Z, Ampudia-Mesias E, Pluhar GE, et al. CD200 immune checkpoint reversal at the site of tumor vaccine inoculation: a novel approach to glioblastoma immunotherapy. Clin Cancer Res. 2019;26:232–241.
- Mahadevan D, Lanasa MC, Farber C, et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J Immunother Cancer. 2019;7:227.
- Xiong Z, Ampudia-Mesias E, Shaver R, et al. Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy. Immunotherapy. 2016;8:1059–1071.
- Moertel CL, Xia J, LaRue R, et al. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. J Immunother Cancer. 2014;2:46.
- Olin MR, Ampudia-Mesias E, and Pennell CA, et al. Treatment combining CD200 immune checkpoint inhibitor and tumor-lysate vaccination after surgery for pet dogs with high-grade glioma. Cancers (Basel). 2019;11;137–148.
- Ampudia-Mesias E, Puerta-Martinez F, Bridges M, et al. CD200 immune-checkpoint peptide elicits an anti-glioma response through the DAP10 signaling pathway. Neurotherapeutics. 2021 Jul;18(3):1980–1994.
- Shen K, Liu T. Comprehensive analysis of the prognostic value and immune function of immune checkpoints in stomach adenocarcinoma. Int J Gen Med. 2021;14:5807–5824.